With Comparable Outcomes, Should Early Stage Lung Cancer Be A Contraindication to Lung Transplant?

CONCLUSIONS: One- and 5-year survival rates were comparable between LTx recipients with incidentally noted pathological Stage I NSCLC and contemporary recipients without cancer. All cancer-related mortality occurred in recipients with incidentally noted advanced NSCLC. These results suggest that patients with pathological Stage I lung cancer at the time of transplant have outcomes comparable to those without cancer findings at the time of transplant.PMID:37704001 | DOI:10.1016/j.athoracsur.2023.09.002

Source: The Annals of Thoracic Surgery - September 13, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Connor S Spies Timothy N Ochoa Arya Pontula Chelsea S Harris Laurie D Snyder Elizabeth N Pavlisko Matthew G Hartwig Source Type: research